文献速递神经头颈儿科影像MR

弥散加权成像-钆增强不匹配征在弥漫性中线胶质瘤中的应用

Diffusion-weighted imaging-gadolinium enhancement mismatch sign in diffuse midline glioma.
PubMed 文献 · Eur J Radiol · 2021-12-13

本研究回顾性纳入2007至2020年本院诊断的21例弥漫性中线胶质瘤(含弥漫性内生性脑桥胶质瘤)患者,均接受54 Gy/30次局部放疗。21例中9例存在DWI-Gd不匹配征,该征阳性者总生存期短于阴性者(9.9个月 vs 18.6个月,P=0.00062)。DWI-Gd不匹配征可能为弥漫性中线胶质瘤不良预后的影像生物标志物。

要点

  • DWI-Gd不匹配征指DWI高信号而钆增强T1WI无强化,在21例弥漫性中线胶质瘤中9例阳性。
  • DWI-Gd不匹配征阳性者总生存期9.9个月,阴性者18.6个月,差异有统计学意义(P=0.00062)。
  • DWI高信号(P=0.0014)与钆增强(P=0.00071)均为显著不良预后标志。

核心结论

  • DWI-Gd不匹配征可能为弥漫性中线胶质瘤不良预后的影像生物标志物。

研究设计与样本

  • 回顾性研究,经本院机构审查委员会批准,纳入2007至2020年本院诊断的弥漫性中线胶质瘤(含弥漫性内生性脑桥胶质瘤)患者21例,均接受54 Gy/30次局部放疗,分析影像特征与预后的关系。

关键影像表现/征象

  • DWI-Gd不匹配征定义为非强化病灶在DWI上呈高信号,21例中9例阳性。
  • DWI上存在高信号(P=0.0014)与钆增强(P=0.00071)为显著不良预后标志。
  • DWI-Gd不匹配征与瘤内出血在丘脑弥漫性中线胶质瘤中较脑桥/弥漫性内生性脑桥胶质瘤更常见(分别为P=0.046和P=0.0017)。

诊断标准与关键数值

  • DWI-Gd不匹配征阳性者总生存期9.9个月,阴性者18.6个月(P=0.00062)。

临床应用与阅片要点

  • 阅片时可关注DWI高信号而钆增强T1WI无强化的不匹配表现,该征阳性者总生存期较短(9.9个月 vs 18.6个月)。
  • 丘脑弥漫性中线胶质瘤中DWI-Gd不匹配征与瘤内出血较脑桥/弥漫性内生性脑桥胶质瘤更常见(P=0.046和P=0.0017)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Diffuse midline glioma (DMG), H3 K27M-mutant including diffuse intrinsic pontine glioma (DIPG) is a disease with dismal prognosis. We focused on diffusion-weighted imaging (DWI) and gadolinium enhanced T1WI (Gd), especially high intensity on DWI at non-enhanced lesion, i.e. DWI-Gd mismatch sign, to establish as an imaging biomarker of DMG patients.

MATERIALS AND METHODS: Our institutional review board approved this retrospective study. Twenty-one patients diagnosed as DMG including DIPG at our institution between 2007 and 2020 were enrolled in this study. All patients underwent local radiotherapy of 54 Gy/30 fractions. We studied the relationship between imaging features including DWI-Gd mismatch sign and prognosis.

RESULTS: DWI-Gd mismatch sign was found in 9 out of 21 DMG patients. Among different imaging characteristics, existence of high intensity on DWI (P = 0.0014), gadolinium enhancement (P = 0.00071) were the significant poor prognostic markers in DMG, which were consistent with the previous reports about DIPG. In our results, positive DWI-Gd mismatch sign was statistically strongest poor prognostic imaging biomarker, and patients with positive DWI-Gd mismatch sign had shorter OS compared to those with negative mismatch sign (9.9 months vs 18.6 months, P = 0.00062). DWI/Gd mismatch sign and intratumoral bleeding were more common in DMG at thalamus compared to DMG at pons/DIPG (P = 0.046 and P = 0.0017, respectively).

CONCLUSIONS: DWI-Gd mismatch sign may be an imaging biomarker for poor prognosis in DMG. (E-1601).

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ikeda, Kolakshyapati, Takayasu, et al. Diffusion-weighted imaging-gadolinium enhancement mismatch sign in diffuse midline glioma. Eur J Radiol. 2021. PMID: 35051691. doi:10.1016/j.ejrad.2021.110103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。